ABSTRACT
RATIONAL: Paragangliomas are rare and can occur in many places throughout the body, but mediastinal paragangliomas are even rarer, accounting for less than 0.3% of mediastinal masses. Extremely susceptible to misdiagnosis and mistreatment, which may lead to the death of the patient. PATIENT CONCERNS: We report a case of a giant paraganglioma of the middle mediastinum. A 40-year-old woman was admitted to the hospital with a rib fracture and a chest computed tomography suggesting a giant occupying tumor in the middle mediastinum. DIAGNOSIS: Immunohistochemistry revealed positive for S100 fraction and Syn, focally positive for CgA, while negative for CKp and succinate dehydrogenase complex iron sulfur subunit B gene, and Ki67indexâ ≈â 5%. The imaging and immunohistochemical features suggested a final diagnosis of Paragangliomas. INTERVENTIONS: This patient underwent lateral open heart surgery to remove a mediastinal mass. OUTCOMES: One month after being discharged, the patient was contacted by phone for a follow-up visit and reported feeling OK. Unfortunately, as of the date of submission, the patient did not come to our hospital for review. LESSONS: Mediastinal paraganglioma as a rare and potentially malignant tumor susceptible to misdiagnosis and mistreatment. Organ pathology examination is the gold standard for diagnosis, and surgery is an important treatment method. A clear diagnosis and thorough preoperative examination are important guarantees for the success of surgery.
Subject(s)
Mediastinal Neoplasms , Paraganglioma, Extra-Adrenal , Paraganglioma , Female , Humans , Adult , Mediastinum/pathology , Paraganglioma/diagnosis , Paraganglioma/surgery , Paraganglioma/pathology , Paraganglioma, Extra-Adrenal/pathology , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/surgery , Mediastinal Neoplasms/pathology , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: E-cadherin, a calcium-dependent cell adhesion molecule, as an important mediator of adhesion and signaling pathway, plays a key role in maintaining tissue integrity. However, the association of E-cadherin expression with clinicopathological features and prognostic value in non-small cell lung cancer (NSCLC) is still controversial. Therefore, the purpose of the study is to explore the clinicopathological features and prognostic value of E-cadherin expression in non-small cell lung cancer by meta-analysis. METHODS: PubMed, EMBASE, Cochrane Library, and Web of Science were searched to collect the studies about expression of E-cadherin and clinicopathological features and prognosis of non-small cell lung cancer. The last search time was May 2020. Stata 15.0 software was used for statistical analysis. RESULTS: A total of 35 studies were included, of which the results showed that high expression of E-cadherin compared with its low expression, for overall survival, HRâ=â0.68 (95% CI:0.64-0.73, Pâ<â.05); for disease-free survival or progression-free survival, HRâ=â0.54 (95% CI: 0.44-0.67); low differentiation of lung cancer compared with moderate and high differentiation, ORâ=â0.40 (95% CI: 0.27-0.58, Pâ<â.05); Advanced lung cancer compared with early stage, ORâ=â0.54 (95% CI: 0.44-0.66, Pâ<â.05); lymph node metastasis compared with non-lymph node metastasis, ORâ=â0.49 (95% CI: 0.31â¼0.77). CONCLUSION: Low expression of E-cadherin is closely related to poor prognosis of patients with NSCLC, promoting tumor staging and lymph node metastasis, inhibiting tumor differentiation as well.
Subject(s)
Cadherins , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Biomarkers, Tumor/metabolism , Cadherins/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/mortality , Disease-Free Survival , Evidence-Based Medicine/methods , Lung Neoplasms/pathology , Lymphatic Metastasis/pathology , Molecular Targeted Therapy/methods , Neoplasm Staging/methods , Prognosis , Progression-Free Survival , Meta-Analysis as Topic , Systematic Reviews as TopicABSTRACT
This article has been withdrawn at the request of the Editor-in-Chief. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.